CoChat

Non-Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two-Sample Bidirectional Mendelian Randomisation Study

Zhang, Zixuan, Burrows, Kimberley, Fuller, Harriett, Speliotes, Elizabeth K., Abeysekera, Kushala W. M., Thorne, James L., Lewis, Sarah J., Zulyniak, Michael A., Moore, J. Bernadette · 2023 · Nutrients
Cited by 13

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Evidence for a role for vitamin D in non-alcoholic fatty liver disease (NAFLD) pathogenesis is conflicting. As Mendelian randomisation (MR) avoids many limitations of conventional observational studies, this two-sample bidirectional MR analysis was conducted to determine the following: (i) whether genetically predicted 25-hydroxyvitamin D [25(OH)D] levels are a risk factor for NAFLD, and (ii) whether genetic risk for NAFLD influences 25(OH)D levels. Single-nucleotide polymorphisms (SNPs) associated with serum 25(OH)D levels were obtained from the European ancestry-derived SUNLIGHT consortium. SNPs associated with NAFLD or NASH (p-value < 1 × 10−5) were extracted from previous studies and supplemented by genome-wide association studies (GWASs) performed in the UK Biobank. These GWASs were done both without (primary analysis) and with (sensitivity analysis) the population-level exclusion of other liver diseases (e.g., alcoholic liver diseases, toxic liver diseases, viral hepatitis, etc.). Subsequently, MR analyses were performed to obtain effect estimates using inverse variance weighted (IVW) random effect models. Cochran’s Q statistic, MR-Egger regression intercept, MR pleiotropy residual sum and outlier (MR-PRESSO) analyses were used to assess pleiotropy. No causal association of genetically predicted serum 25(OH)D (per standard deviation increase) with risk of NAFLD was identified in either the primary analysis: n = 2757 cases, n = 460,161 controls, odds ratio (95% confidence interval): 0.95 (0.76, −1.18), p = 0.614; or the sensitivity analysis. Reciprocally, no causal association was identified between the genetic risk of NAFLD and serum 25(OH)D levels, OR = 1.00 (0.99, 1.02, p = 0.665). In conclusion, this MR analysis found no evidence of an association between serum 25(OH)D levels and NAFLD in a large European cohort.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu15061442

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 46

  1. Younossi, 2018, Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, Nat. Rev. Gastroenterol. Hepatol., 15, 11, 10.1038/nrgastro.2017.109 · DOI · Paper page
  2. Bence, 2021, Metabolic drivers of non-alcoholic fatty liver disease, Mol. Metab., 50, 101143, 10.1016/j.molmet.2020.101143 · DOI · Paper page
  3. 2021, Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations, Semin. Liver Dis., 41, 248, 10.1055/s-0041-1729971 · DOI
  4. Moore, 2019, From sugar to liver fat and public health: Systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis, Proc. Nutr. Soc., 78, 290, 10.1017/S0029665119000570 · DOI · Paper page
  5. Gibson, 2018, Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease, Pediatr. Obes., 13, 433, 10.1111/ijpo.12293 · DOI
  6. Barchetta, I., Cimini, F.A., and Cavallo, M.G. (2020). Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients, 12. · DOI · Paper page
  7. Pacifico, 2019, Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables, Mini Rev. Med. Chem., 19, 310, 10.2174/1389557518666181025153712 · DOI
  8. Karatayli, 2020, Vitamin D in Preclinical Models of Fatty Liver Disease, Anticancer Res., 40, 527, 10.21873/anticanres.13981 · DOI
  9. Roth, 2012, Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation, Hepatology, 55, 1103, 10.1002/hep.24737 · DOI · Paper page
  10. Ma, 2020, Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model, Clin. Res. Hepatol. Gastroenterol., 44, 513, 10.1016/j.clinre.2019.10.007 · DOI
  11. Rhee, 2013, High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome, Endocr. J., 60, 743, 10.1507/endocrj.EJ12-0387 · DOI
  12. Liu, 2020, Association of serum vitamin D level and nonalcoholic fatty liver disease: A meta-analysis, Eur. J. Gastroenterol. Hepatol., 32, 140, 10.1097/MEG.0000000000001486 · DOI
  13. Targher, 2007, Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease, Nutr. Metab. Cardiovasc. Dis., 17, 517, 10.1016/j.numecd.2006.04.002 · DOI · Paper page
  14. Eraslan, 2013, Frequency of metabolic syndrome and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver disease, Minerva Med., 104, 447
  15. Nelson, 2016, Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults with Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB?, Am. J. Gastroenterol., 111, 852, 10.1038/ajg.2016.51 · DOI · Paper page
  16. Zhang, 2019, Vitamin D and nonalcoholic fatty liver disease, Curr. Opin. Clin. Nutr. Metab. Care, 22, 449, 10.1097/MCO.0000000000000605 · DOI
  17. Smith, 2003, ’Mendelian randomization‘: Can genetic epidemiology contribute to understanding environmental determinants of disease?, Int. J. Epidemiol., 32, 1, 10.1093/ije/dyg070 · DOI · Paper page
  18. Wang, 2018, Vitamin D and nonalcoholic fatty liver disease: Bi-directional mendelian randomization analysis, eBioMedicine, 28, 187, 10.1016/j.ebiom.2017.12.027 · DOI
  19. Yuan, 2022, Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease, Clin. Gastroenterol. Hepatol., 21, 398, 10.1016/j.cgh.2022.01.021 · DOI
  20. Jiang, 2018, Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels, Nat. Commun., 9, 260, 10.1038/s41467-017-02662-2 · DOI · Paper page
  21. Wolk, 2017, The seasonal importance of serum 25-hydroxyvitamin D for bone mineral density in older women, J. Intern. Med., 281, 167, 10.1111/joim.12563 · doi:10.1111/joim.12563
  22. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., and Landray, M. (2015). UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med., 12. · DOI · Paper page
  23. Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z · DOI · Paper page
  24. Eslam, 2020, Genetic contributions to NAFLD: Leveraging shared genetics to uncover systems biology, Nat. Rev. Gastroenterol. Hepatol., 17, 40, 10.1038/s41575-019-0212-0 · DOI · Paper page
  25. Hemani, 2018, The MR-Base platform supports systematic causal inference across the human phenome, eLife, 7, e34408, 10.7554/eLife.34408 · DOI · Paper page
  26. Pritchard, 2001, Linkage disequilibrium in humans: Models and data, Am. J. Hum. Genet., 69, 1, 10.1086/321275 · DOI · Paper page
  27. Li, 2021, Contribution of Rs780094 and Rs1260326 Polymorphisms in GCKR Gene to Non-alcoholic Fatty Liver Disease: A Meta-Analysis Involving 26,552 Participants, Endocr. Metab. Immune Disord. Drug Targets, 21, 1696, 10.2174/1871530320999201126202706 · doi:10.2174/1871530320999201126202706
  28. Pierce, 2011, Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants, Int. J. Epidemiol., 40, 740, 10.1093/ije/dyq151 · DOI · Paper page
  29. Burgess, 2013, Mendelian randomization analysis with multiple genetic variants using summarized data, Genet. Epidemiol., 37, 658, 10.1002/gepi.21758 · DOI · Paper page
  30. Bowden, 2015, Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression, Int. J. Epidemiol., 44, 512, 10.1093/ije/dyv080 · DOI · Paper page
  31. Bowden, 2016, Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator, Genet. Epidemiol., 40, 304, 10.1002/gepi.21965 · DOI · Paper page
  32. Walker, 2019, Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes, Wellcome Open Res., 4, 113, 10.12688/wellcomeopenres.15334.1 · DOI
  33. Cohen, 2015, Cochran’s Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy, J. Clin. Epidemiol., 68, 299, 10.1016/j.jclinepi.2014.09.005 · DOI · Paper page
  34. Verbanck, 2018, Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases, Nat. Genet., 50, 693, 10.1038/s41588-018-0099-7 · DOI · Paper page
  35. Rezaei, 2021, The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis, Front. Pharmacol., 12, 732496, 10.3389/fphar.2021.732496 · DOI
  36. Bjelakovic, 2021, Vitamin D supplementation for chronic liver diseases in adults, Cochrane Database Syst. Rev., 8, CD011564
  37. Zhang, Z. (2022). Vitamin D and the Molecular Pathogenesis of Non-alcoholic Fatty Liver Disease. [Ph.D. Thesis, University of Leeds].
  38. Hayward, 2021, Detecting non-alcoholic fatty liver disease and risk factors in health databases: Accuracy and limitations of the ICD-10-AM, BMJ Open Gastroenterol., 8, e000572, 10.1136/bmjgast-2020-000572 · DOI
  39. Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, J. Hepatol., 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
  40. Ahn, 2010, Genome-wide association study of circulating vitamin D levels, Hum. Mol. Genet., 19, 2739, 10.1093/hmg/ddq155 · DOI · Paper page
  41. Wang, 2010, Common genetic determinants of vitamin D insufficiency: A genome-wide association study, Lancet, 376, 180, 10.1016/S0140-6736(10)60588-0 · DOI · Paper page
  42. Hartwig, 2021, Bias in two-sample Mendelian randomization when using heritable covariable-adjusted summary associations, Int. J. Epidemiol., 50, 1639, 10.1093/ije/dyaa266 · DOI · Paper page
  43. Luukkonen, 2015, Heterogeneity of non-alcoholic fatty liver disease, Liver Int., 35, 2498, 10.1111/liv.12970 · DOI
  44. Jiang, T., Gill, D., Butterworth, A.S., and Burgess, S. (2022). An empirical investigation into the impact of winner’s curse on estimates from Mendelian randomization. Int. J. Epidemiol. · doi:10.1101/2022.08.05.22278470
  45. Tilling, 2018, Collider scope: When selection bias can substantially influence observed associations, Int. J. Epidemiol., 47, 226, 10.1093/ije/dyx206 · DOI · Paper page
  46. Kim, M.S., Song, M., Shin, J.I., and Won, H.H. (2023). How to interpret studies using Mendelian randomisation. BMJ Evid.-Based Med., in press. · DOI

Metadata

Authors
Zhang, Z., Burrows, K., Fuller, H., Speliotes, E. K., Abeysekera, K. W. M., Thorne, J. L., Lewis, S. J., Zulyniak, M. A., & Moore, J. B.
Venue
Nutrients
Publisher
MDPI AG
Published
2023-03-16
Volume
15
Issue
6
Pages
1442
ISSN
2072-6643
Cited by
13
References
11
Language
en
Funders
  • Cancer Research UK (C18281/A29019, BRC-1215-20011, 217446/Z/19/Z)
  • NIHR (C18281/A29019, BRC-1215-20011, 217446/Z/19/Z)
  • Wellcome Trust (C18281/A29019, BRC-1215-20011, 217446/Z/19/Z)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two-Sample Bidirectional Mendelian Randomisation Study. https://app.cochat.ai/papers/10.3390/nu15061442
The paper
Zhang, Z., Burrows, K., Fuller, H., Speliotes, E. K., Abeysekera, K. W. M., Thorne, J. L., Lewis, S. J., Zulyniak, M. A., & Moore, J. B. (2023). Non-Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two-Sample Bidirectional Mendelian Randomisation Study. Nutrients. https://doi.org/10.3390/nu15061442

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.